Scienture receives FDA approval for Arbli (losartan oral suspension); launch planned Q3 2025

Scienture Holdings, Inc.

FDA approves SCN-102 as Arbli (losartan potassium oral suspension), first liquid ready-to-use losartan in US.
Arbli indicated for hypertension (age >6), stroke risk reduction, diabetic nephropathy.
US losartan market $292M annual sales, 68M prescriptions (IQVIA Dec 2024); global $1.5B.
Commercial launch expected Q3 2025; product has 18-month shelf life at room temp.
Consulting agreement with Draper Inc. for IR/business dev: 100k shares initial + 100k/mo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.